Sideris Pharmaceuticals Report issue

For profit Phase 1
Founded: Lexington MA United States (2012)
Status: Acquired by Novartis (2013)

Organization Overview

First Clinical Trial
2014
NCT02274233
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Sideris Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 1 Trials (1)

sp-420 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

beta-Thalassemia (Phase 1)

Iron Overload (Phase 1)

Thalassemia (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1